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Abstract 
This review intends to act as an overview of Fructose Malabsorption (FM) and its role in the 
aetiology of diseases including, but not limited to, Irritable Bowel Syndrome (IBS) and Infantile 
colic and the relationship between fructose absorption and the propagation of some cancers. 
IBS results in a variety of symptoms including stomach pains, cramps and bloating. Patients 
can be categorised into two groups, depending on whether the patients’ experiences either 
constipation (IBS-C) or diarrhoea (IBS-D).  Fructose Malabsorption has been proposed as a 
potential cause of IBS-D and other diseases, such as infantile colic. However, our knowledge 
of FM is limited by our understanding of the biochemistry related to the absorption of 
fructose in the small intestine and FM’s relationship with Small Intestinal Bacteria Overgrowth 
(SIBO). It is important to consider the dietary effects on FM and most importantly, the 
quantity of excess free fructose consumed. The diagnosis of FM is difficult and often requires 
indirect means that may result in false positives. Current treatments of FM include dietary 
intervention, such as low fermentable oligo-, di-, mono-saccharides and polyols (FODMAP) 
diets and enzymatic treatments, such as the use of xylose isomerase. More research is needed 
to accurate diagnose and effectively treat FM. This review is designed with the goal of 
providing a detailed outline of the issues regarding the causes, diagnosis and treatment of 
FM. 
Keywords: Fructose Malabsorption, Irritable bowel syndrome, small intestines, diagnosis, 
breath hydrogen testing. 
Abbreviations 
IBS: Irritable Bowel Syndrome 
FM: Fructose Malabsorption 
GI: Gastrointestinal  
HFCS: High Fructose Corn Syrup 
GLUT: Glucose Transporter 
SLC2A5: Solute carrier family 2, facilitated glucose transporter member 5 
RNA: Ribonucleic acid 
SIBO: Small Intestinal Bacterial Overgrowth 
DP: Degree of polymerization  
EFF: Excess Free Fructose 
Hydrogen Breath Test: HBT 
FODMAP: fermentable oligo-, di-, mono-saccharides and polyols 
Introduction 
It is estimated that Irritable Bowel Syndrome (IBS) affects around 11% of the global 
population.(1) IBS has symptoms including stomach pains and cramps, bloating, diarrhoea and 
constipation. Although being a common disease, the exact causes of IBS are typically 
described as a gut-brain disorder, however, this notion has been challenged in recent years 
and a number of new potential causes, including anxiety and depression, gut bile 
malabsorption and inflammation and infection of the nervous system, have been proposed.(2)  
Fructose Malabsorption (FM) has also been suggested as a potential cause of IBS.(3) FM is 
believed to affect 1 in 3 patients with IBS and is caused by the incomplete absorption of 
fructose in the Small Intestine (SI), leading to gastrointestinal (GI) complaints and has been 
linked to other diseases, such as early-stage depression. (4–6) FM can develop as a result of 
primary causes, such as congenital deficiency, or by secondary means, including, but not 
limited to intestinal damage, acute gastroenteritis, medication, coeliac disease, Crohn’s 
diseases and use of prebiotics. However, due to a lack of knowledge regarding the mechanism 
of fructose absorption to date, it has been difficult to accurately diagnose and treat FM.(7) In 
the past few decades, there has been an increase in the amount of fructose consumed, 
particularly due to High Fructose Corn Syrup (HFCS) and increased consumption of HFCS-rich 
soft drinks, especially by younger people.(8) It has been noted in a survey between 1994 and 
1996, that the consumption of artificial sweeteners, including HFCS, results in 318 kcal daily 
of dietary consumption for US Americans above the age of two; this accounts for 16 % of all 
caloric intake daily.(9)   
A variety of diseases can result in the malabsorption of sugars, include lactose intolerance, 
congenital glucose–galactose malabsorption and Congenital Sucrase-Isomaltase deficiency, 
resulting in the malabsorption of lactose, galactose and maltose respectively.(10,11) However, 
this review will focus on FM and the specific factors affecting the treatment of FM. 
Fructose chemistry 
Fructose, a ketonic monosaccharide, is able to be directly absorbed into blood from the GI 
tract; it is one of three dietary monosaccharides that possess this property, alongside glucose 
and galactose Fructose is commonly obtained from sugar beets, sugar cane and maize and is 
the sweetest of all monosaccharides.(12) The solubility and sweetness of fructose has been 
exploited by the food industry in artificial sweeteners, with particular popularity around the 
use of HFCS, a mixture of glucose and fructose in the monosaccharide form in recent years. 
Between 1970 and 2004, the share of HFCS as a percentage of total sweetener use has risen 
from half a percentage point, to forty-two percent.(13)  
It has been estimated that between 1994 and 1998, the average US American above the age 
of two consumes 132 kcal of HFCS per day. Added sweeteners contribute to sixteen percent 
of this daily calorific intake.(14–16) Fructose can be present as a monosaccharide, most 
abundantly in the furanose form, or as the disaccharide sucrose, in a one to one molecular 
ratio with glucose. Figure 1 shows the five isomers of fructose; in aqueous solution, fructose 
exists in the equilibria shown in figure 1. The mixture of the five isomers is comprised of 
seventy percent fructopyranose and twenty two percent fructofuranose; the remaining eight 
percent consists of the other three forms, including acyclic D-fructose. Fructose can also exist 
in two anomeric states, α and β and these are also shown in figure 1.  
 
Figure 1: Structures of the isomers and anomers of fructose 
Causes of Fructose Malabsorption 
Fructose Malabsorption is be caused by the failure to effectively absorb fructose through the 
enterocytes lining the small intestines. This results in the accumulation of fructose in the 
intestinal lumen. The resulting change in osmotic pressure causes the flow of water into the 
lumen, thus leading to the symptoms associated with IBS. The underlying factors related to 
the cause of FM will be described in detail in the following section. 
Mechanism of fructose absorption 
For healthy patients, serum fructose concentration is around 8.1 ± 1.0 μmolL-1 and for 
diabetics, serum fructose concentration is around 12.0 ± μmolL-1.(17) The current 
understanding of FM is underpinned by the transport enzymes present on the borders of the 
enterocytes lining the small intestine. The two enzymes in question are Glucose Transporters 
(GLUT) GLUT2 and GLUT5. The general understanding of the mechanism of absorption for 
fructose is that GLUT2 is a high-capacity, low-affinity glucose/galactose transporter that can 
co-transport fructose in a one-one ratio.(18) GLUT2 is unable to transport fructose without the 
presence of glucose, although the mechanism for this is currently unknown. However, it is 
proposed that GLUT5 is able to selectively transport fructose across the apical membrane of 
the small intestine. The low capacity of GLUT5 means that excess fructose leads to the 
overloading of GLUT5, preventing the complete absorption of fructose.(19) The presence of 
excess fructose in the GI tract leads to increased osmotic load, which, in turn, triggers the 
symptoms associated with IBS.(4) Further research is needed to solidify our understanding of 
fructose absorptions, so that treatment can be better targeted. One such method could 
involve targeting the prevention of the fructose accumulation in the GI tract, thus preventing 
the symptoms resulting from such accumulation. Figure 2 summarises the enzymes involved 
in the absorption of fructose and other dietary sugars, in the small intestine. It shows the 
confirmed and proposed locations of GLUT5 within the enterocyte.(20) 
 
Figure 2: A simplified diagram of sugar transporters in the enterocytes of the small intestines. Adapted from(21–
23).  SGLT-1 Is a sodium-mediated enzyme related the facilitated co-transport of glucose and galactose and is not 
linked to the transportation of fructose(24) 
A total of six glucose transporters potentially have the capacity to selectivity transport 
fructose. These are GLUTs 5, 7,8, 9, 11 and 12.(20) However, this review will focus primarily on 
GLUT5, due to its confirmed selectivity for fructose and its high expression within the small 
intestine and duodenum.   
Expression of GLUT5 
Expression of GLUT5 is coded by the Solute carrier family 2, facilitated glucose transporter 
member 5 (SLC2A5) gene and although expression is highest in the small intestine and 
duodenum, the ribonucleic Acid (RNA) resulting from SLC2A5 expression is found in other 
tissue as well.(25) Despite glucose being the primary energy source in the brain, RNA 
production from SLC2A5 has resulted in GLUT5 expression being found in the blood-brain 
barrier of rats, as well as the microglia and foetal cerebellar Purkinje cells of humans. (26–28)  
GLUT5 is also expressed in the cerebellum of mice and the hippocampus of rats. These cells 
may be capable of using fructose as a source of energy; however, this is currently 
unconfirmed. It should be noted the expression of GLUT 5 in the brain is significantly lower 
than in the small intestine.(29) 
Diabetes has a major effect on GLUT5 expression in the small intestine. It has been found that 
in type 2 diabetic patients, there is a three to four-fold increase in the expression of GLUT 5 
proteins and mRNA in duodenal and small intestinal cells.(29) Reversing blood hyperglycaemia 
results in the reversal of the elevated levels of GLUT 5 expression.(29) A positive link between 
blood hypertension, linked to diabetes and upregulation of GLUT5 has also been 
investigated.(17) However, more research into this finding is required. 
The effect diabetes has on serum fructose concentration is currently unclear. Serum fructose 
concentration and urinary fructose increased significantly in Japanese diabetic patients 
indicating FM.(30) However, a similar study in Finland, comparing healthy volunteers with type 
1 and 2 diabetics indicated similar concentrations of serum fructose.(31,32) These contradictory 
results complicate what the precise effect of diabetes is on serum fructose concentration. 
However, it is apparent that fructose may have a key role in the development of metabolic 
disorders that cause the adverse effects resulting from diabetes. 
FM may have a role to play in causing infantile colic.(33) It has been noted that in the prenatal 
and suckling periods of rats, rabbits and humans, GLUT5 levels in the intestine are very low. 
(34) Additionally, a study into breath hydrogen of colic-affected patients, indicated an increase 
in breath hydrogen in children, less than one year of age, but not in those two years or 
older.(35) These results indicate that GLUT5 is not initially expressed in infants and the resulting 
FM may result in the colic that many infants suffer from. 
Interestingly, elevated levels of GLUT5 mRNA and protein expression have been found in 
some cancer cell lines. Despite GLUT5’s poor expression in typical mammary epithelial cells, 
high amounts of GLUT5 mRNA and protein expression have been found in the breast 
carcinoma cell lines MCF-7 and MDA-MB-231, resulting in high fructose transport rates(36), 
which are models of early and late stage cancer respectively. GLUT5 knockdown studies have 
shown inhibition of the growth of both MCF-7 and MDA-MB-231, highlighting the 
transporter’s importance to the cancer cell lines.(37) 
Large scale screening of the GLUT family, using western blotting, in both cancerous and 
normal human tissue, showed GLUT5 is significantly overexpressed in twenty-seven percent 
of cancerous tissues tested, including tumours of the brain, breast, colon, liver, lung, testes 
and uterus, with GLUT5 showing moderate to high amounts of staining in all but one cancer 
tissues tested.(36,37) 
Most of the tumours cells presenting an overexpression of GLUT5 additionally possess an 
elevated rate of fructose uptake and the extensive overexpression of GLUT2 and GLUT5, 
indicate that fructose may be preferred as the energy source for the growth and propagation 
of some tumour cells. (38) More research is needed to determine whether this characteristic 
can be exploited for anti-cancer activity. It could be possible locally inducing FM in cancer 
cells, may result in apoptosis of such cells. The impact of the GLUT5’s presence in some 
cancerous tissue needs to be fully delineated, to confirm whether GLUT5 can be exploited as 
a target for novel chemotherapy methods. 
Small Intestinal Bacterial Overgrowth (SIBO) 
It has been proposed that some symptoms of IBS may not be as a result of FM, but rather as 
a result of fructose fermentation by bacteria in the small intestine and the resulting bacterial 
respiration.(39) These symptoms include, bloating and elevated Hydrogen Breath Test (HBT) 
levels.  Hydrogen gas excretion is significantly increased in eighty four percent of IBS patients 
after lactulose ingestion (BTLact) and an increase of seventy five percent after the use of local 
antibiotics. There is also a strong correlation between the nature of gas excreted and bowel 
movement patterns.(40,41)  
The BTLact test is a tool used to assess the prevalence of SIBO within a patient. When 
compared to analysing jejune aspiration, BTLact is simpler and more tolerable for patients, 
providing information quicker to the clinician, since a jejune aspiration testing requires an 
endoscopic retrieval of jejunal flora and subsequent microbiological culture.(41) 
BTLact uses the ingestion of lactulose, which cannot be absorbed through the small intestine, 
resulting in the lactulose being metabolised by bacterial flora, producing gases, including 
methane and hydrogen. 
The sensitivity of the BTLact test in SIBO diagnosis is reported to be sixty eight percent, with 
forty four percent specificity, indicating that some symptoms of IBS may not be due to SIBO 
exclusively.(44–46) This has directed some clinicians to consider that BTLact is not the best 
method for diagnosing SIBO and they prefer more indirect methods, such as serum vitamin 
B12 and folate levels instead. It must also be noted that BTLact uses lactulose; this is significant 
because the flora of the small intestine is varied and complex (and may respond differently 
to other sugars, including fructose and fructans). Currently, there is no standardized test for 
the absorption of fructans and research in the area is limited.(47,48) 
Fructans are naturally derived carbohydrate storage polymers found in plants. They are 
fructose polymers with terminal glucose molecules. The degree of depolymerisation (DP), 
defined as the number of monomers that make up an oligomer or polymer, thereby indicating 
the length of the oligomer or polymer, can be a low as one and can reach several hundreds.(49) 
A couple of examples of common fructans are sucrose (DP = one) and insulin (DP = thirty five). 
Fructans are typically found in cereals, onions, asparagus, scornzonera and Jerusalem 
artichokes, as well as some nonedible plants, for example, chicory.(40) Fructans are commonly 
used as artificial sweeteners.(40) It has been shown that dietary fructans can alter the intestinal 
mucosal environment, releasing mucins and mucosa-associate bifidobacterial in gnotobiotic 
rats.(41) Fermentation patterns of fructans tend to remain fairly consistent regardless of DP, 
however, there is a significant positive correlation between DP and transit time.(51) However, 
the same study showed that undesired abdominal symptoms only occurred in single doses of 
fructans greater than 20 g where given to the participants of a trial.(52) 
These studies indicate that some symptoms of IBS perhaps are better attributed to SIBO, 
rather than FM alone. However, it must be noted that the two conditions are not mutually 
exclusive; rather, it is important to note that a patient with IBS may have SIBO and FM, or only 
one of the two conditions. Since it is apparent that the symptoms of IBS cannot be exclusively 
attributed to one of these two causes, the nature of their interactions may cause difficulty 
when attempting to determine the appropriate therapeutic actions to pursue. This is because 
certain treatments that are affective for symptoms resulting in SIBO may be ineffective for 
symptoms resulting from FM and vice versa.(53) 
It has also been proposed that the uses of prebiotics have a beneficial effect on intestinal 
health.(54) However, this may result in SIBO and the production of unwanted side-effects in 
patients affected by IBS. Prebiotics can selectively stimulate the growth and activity of gut 
bifidobacteria and lactobacilli.(55,56) Prebiotics are non-digestible, short chain carbohydrates 
with a DP between two and approximately sixty. However, this evidence related to non-
digestible prebiotics is mostly circumstantial. Oligofructose that has been incubated in vivo 
with either human saliva or rat pancreatic homogenate has been shown to be ‘hardly 
digested’, rather than completely non-digestible.(51) This means that oligofructose may 
contribute to the accumulation of fructose in the GI tract. Prebiotics are relatively simple, 
water soluble, molecules; therefore, fermentation by gastrointestinal flora is highly likely.  
Human studies have shown a consistent failure to recover inulin and oligofructose in faecal 
matter, indicating their complete metabolization by intestinal flora.(57) In vitro studies have 
demonstrated the ability of prebiotics to support intestinal bacteria growth and result in the 
production of a variety of fermentation-derived end products.(58) Two early studies showed 
the in vitro utilisation of oligofructose, derived from sucrose, by bifidobacteria. However, 
oligofructose lacks selectivity towards bifidobacterial species and a variety of enteric bacteria 
were able to grow on a wide range of prebiotics, in particular, species of Bacteroides.(59,60) 
Wang and Gibson later showed that both inulin and oligofructose could selectively promote 
the growth of bifidobacteria.(61)  It has been shown that forty-two percent of patients with 
FM also have a high prevalence of intestinal parasites, with Girardia intestinalis being present 
in twenty six and a half percent of cases of FM, highlighting a significant association between 
FM and the presence of intestinal parasites.(62) 
The main products of the metabolism of prebiotics are short chain fatty acids, hydrogen gas, 
carbon dioxide and bacterial cell mass.(63) However, there has been little research into the 
relationship of the type of carbohydrate and its fermentability. This research could provide 
profound insight into the effect prebiotics have upon the symptoms of IBS resulting from 
SIBO. 
Trends in the diagnosis of fructose malabsorption 
A number of different factors have been linked to an increased likelihood of developing FM. 
It is important to consider these factors, as FM is often misdiagnosed, due to the similarity in 
symptoms with other forms of carbohydrate malabsorption. 
A key difference in FM cases when compared to lactose intolerance and other cases of 
carbohydrate malabsorption, is the relationship between FM and age. A study of one 
thousand and ninety three patients showed that the probability of testing positive for FM 
decreased by a factor of 0.82 per year of age, for patients under the age of fifteen; this trend 
is not found in cases of lactose intolerance.(64) This may be linked with the late expression of 
fructose-selective GLUT5 enzymes.(34) 
There may also be a relationship between gender and FM. A study in 2007 showed that 
women complained more frequently about symptoms associated with FM (p = 0.04) as well 
as presenting a greater number of cases than men (p = 0.0.0527).(65) However, this study 
needs expansion to a larger sample size (greater than n = 29) and more research is needed to 
determine whether there is a causal link between gender and FM. 
Unfortunately, there has been no research into comparing the pervasiveness of FM between 
different ethnicities on a national level. Therefore, it is currently difficult to determine any 
possible correlation between ethnicity and the likelihood of FM.  
Diet is a key factor in the prevalence of FM. A study of 3476 patients with FM showed that 
fifty-two percent of patients consumed a fructose-rich diet; including high consumption of 
soft drinks, fruit juices, candy and fructose-rich fruits, including apples, pears, peaches and 
oranges. The effects of diet on FM will be discussed in more detail later on in this review.(66) 
According to the same study, FM is most commonly accompanied by gastroesophageal reflux 
disease, followed by lactose intolerance.(66) It should be noted again that the symptoms of 
lactose intolerance are similar to those of FM, which may lead to potential misdiagnosis of 
FM. 
Effect of diet relating to fructose malabsorption 
It is important to consider the trends in fructose consumption and the changes in diet related 
to sugar that may contribute towards FM and diseases caused, at least in part, by FM.  
Logically, it could be expected that high fruit consumption is a primary cause of FM because 
of its sugar content. However, based upon the hypothesis that the critical factor is the amount 
of excess free fructose (EFF), many fruits may not fit this criterion. According to a study by 
Barrett and Gibson on sugar content in fruits, only apples, pears, mangoes and Asian pears 
have more than a gram of EFF per average serving, potentially leading to FM after 
consumption. All other fruits contain fructose, with either glucose in excess, or a very slight 
excess in fructose, making them an unlikely factor for FM.(8) Another key component here is 
the consumption of soft beverages, which often use HFCS as an artificial sweetener; which is 
high in fructose. Studies by Ventura and Walker have shown that the vast majority of soft 
drinks in North America contain of EFF.(14,63) The study by Ventura assessed that 18 soft-drinks 
that used HFCS had an average of 1.5 g of EFF per 100 mL, this results in an average of thirty 
seven percent more fructose than glucose.(14) Two notable exceptions are Mexican Coca-Cola 
and Pepsi throwback, which both use cane sugar, rather than HFCS. Walker’s study showed 
Cane sugar has a lower fructose quantity than HFCS, the two beverages using cane sugar 
recorded an average of 0.25 g of EFF per 100 mL; resulting in 5.6 percent more fructose than 
glucose for the two drinks.(14,63) Although there are other harmful health effects of soft drink 
consumption that may be reduced by the introduction of HFCS, its introduction in recent 
times has likely caused an increased risk of FM, particularly in communities where soft drink 
consumption is high. 
It is estimated that, on average, 10% of an US American’s daily calorie intake is derived from 
fructose.(8) A study by Vos et al  assessed that, fructose consumption per capita in Americans 
(excluding that which occurs naturally in fruits and vegetables) increased from less than 0.5 
g/day in 1970 to more than 40 g/day in 1997.(8) This may be due to the increase in 
consumption of HFCS, with consumption increasing by 26 percent, from 64 g/day in 1970 to 
81 g/day in 1997. HFCS, contains fructose (55% by weight; 56.7% of total calories) and glucose 
(42% by weight; 43.3% of total calories) in their monosaccharide forms, thus highlighting a 
potential increase in fructose consumption from HFCS.(15) 
Another study by Vos et al, in 2008, provided important statistics on fructose consumption. 
Fruit and fruit juices provide the largest amount of fructose children aged 2-5 years and for 
adults over the age of 50, whereas for people aged between 12 and 30, sugar-sweetened 
drinks account for nearly half of all fructose consumption, perhaps due to HFCS.(8) The study 
found that processed food, regardless of food category, is responsible for a significant 
contribution towards fructose consumption. Seventy-four percent of fructose consumed 
originated from foods excluding whole foods and vegetables.(8) It is important to highlight 
that this data is from the USA; surveys for other countries are limited and conclusions drawn 
from other territories may differ significantly, especially due to the local availability of HFCS. 
A study of national HFCS production and diabetes prevalence was conducted by Goran et al 
in 2013.(67) It was found that there is a twenty percent increase in the prevalence of type-two 
diabetes in HFCS-producing countries, with a p-value = 0.013. Although the values in the paper 
are skewed by the significantly higher than average prevalence of type 2 diabetes in the USA 
(this study examined type 2 diabetes), it could be argued that due to the estimates of HFCS 
production, that fructose malabsorption prevalence may follow a similar trend. 
Diagnosis of Fructose Malabsorption 
Diagnosing FM is made difficult due to the fact that symptoms caused by FM can be caused 
by a number of other conditions, including other sugar intolerances. The current test for FM 
is the Hydrogen Breath Test (HBT).(68) Excess sugar in the GI tract is fermented by intestinal 
bacteria, resulting in the production of hydrogen which can be measured during exhalation. 
The chemical reaction for this is shown in figure 3. The patient is given pure fructose to 
consume and after a period of fasting (usually between 8-12 hours), the patient’s breath is 
collected and analysed for the concentration of gases in the breath sample. Elevated levels of 
hydrogen may indicate the patient suffers from FM. Typically, a positive test is recorded is the 
concentration of Hydrogen and Methane are greater than 20 ppm above baseline values, 
recorded prior to the test, after 60 minutes. (69)  
C6H12O6   +  H2O     → C2H4O2 + C4H6O5 + 2H2 
Fructose +  Water →  Acetic acid + Malic acid + Hydrogen  
 
C4H6O5 → C3H6O3 + CO2 
Malic acid → Lactic acid + Carbon dioxide 
 
2C6H12O6 + 2H2 → 2C6H14O6  
Malic acid + Hydrogen → Mannitol 
Figure 3: Chemical reaction for the fermentation of fructose by bacteria in the GI tract.(70)  
However, there are a number of issues with the HBT. Lee’s group estimated that between 
eight and twelve percent of all patients tested for lactose malabsorption will result in false 
negatives from the HBT, if tested for hydrogen alone, since many patients will produce 
methane, rather than hydrogen.(71) A key problem with the HBT is the lack of specificity of the 
test; elevated breath hydrogen can be as a result of a multitude of reasons, including FM, but 
also potentially SIBO and malabsorption of other carbohydrates, which will need alternative 
treatments. Furthermore, subjective assessment of diet is needed to fully assess the 
gastrointestinal complaints and misdiagnosis is possible. In addition, a number of HBTs result 
in false positives, leading to inaccurate data in the epidemiology of FM. In order to accurately 
diagnose FM, a fructose-selective analysis of the GI tract is required. Helwig et al described 
the HBT as possessing no predictive value for the outcome of fructose-free diets, indicating 
doubt in the HBT’s ability as a predictive test for FM. However, Helwig did also describe a 
positive correlation between the concentration of Hydrogen measured in the HBT and the 
prevalence of FM symptoms, indicating some validity to the use of HBT.(72) Fructose 
malabsorption cannot be directly diagnosed via the Rome criteria, used for gastrointestinal 
complaints. The Rome criteria, used to diagnosed IBS, is in its’ forth iteration and requires a 
patient to have recurrent abdominal pain at least once a week for three months, accompanied 
by at least two of the following for a positive diagnosis of IBS: a change in stool frequency, a 
change in stool form, or discomfort during defecation.(73,74) 
Treatment of fructose malabsorption 
The primary method of treating gastrointestinal complaints, such as IBS, is through dietary 
change. A common diet change is the low-Fermentable Oligo-, Di-, Monosaccharide And 
Polyol (FODMAP) diet. This is a restrictive diet aimed at limiting the group of carbohydrates 
that are poorly absorbed in the small intestine and subsequently fermented by intestinal 
bacteria. Table 1 shows a list of foods that may be prescribed as part of a low FODMAP diet. 
It should be noted that Tuck et al showed that the simple addition of glucose to fructose had 
no effect on HBT results of patients with symptoms of FM, when compared to fructose 
consumption alone.(75) 
 
Types of sugars High FODMAPs food Low FODMAP alternatives 
Oligosaccharides FOS 
Grains: wheat-, rye- and barley-based 
products 
Vegetables: onion, garlic, artichokes, 
leeks, beetroot and savoy cabbage 
Fruits: watermelon, peaches, persimmon, 
prunes, nectarines and most dried fruit 
GOS 
Legumes: red kidney beans, baked beans 
and soya beans 
Vegetables: beetroot and peas 
Fruit: banana, most berries (except boysenberries and 
blackberries), grapes, lemon, lime, mandarin, orange, 
kiwi fruit, pineapple, passion fruit and rhubarb 
Vegetables: capsicum, bok choy, green beans, 
parsnip, silverbeet, cucumber, carrots, celery, 
eggplant, lettuce, potatoes, yams, tomatoes and 
zucchini 
Grains: wheat-free grains/flour, gluten-free bread or 
cereal products and quinoa 
Disaccharides Lactose 
Dairy products: cows/goat milk and 
yoghurt 
Dairy products: lactose-free, almond or rice-based 
milk, yoghurt and ice cream, hard cheese, feta and 
cottage cheese 
Monosaccharides Fructose (in excess of glucose) 
Fruits: apples, pears, watermelon, mango, 
cherries, boysenberries and fruit juice 
from high-fructose foods 
Honey 
Sweeteners: high-fructose corn syrup 
Vegetable: asparagus and snap peas 
Fruit: banana, grapes, honeydew, melon, kiwifruit, 
lemon, lime, mandarin, orange, passionfruit, pawpaw 
and most berries (except boysenberries and 
blackberries) 
Sweeteners: maple syrup and golden syrup 
Polyols Sorbitol 
Fruit: apples, pears, avocado, apricots, 
blackberries, nectarines, peaches, plums, 
prunes and watermelon 
Mannitol 
Vegetables: sweet potato, mushrooms, 
cauliflower and snow peas 
Sweeteners: Maple syrup and sugar (sucrose) 
Fruits: banana, grape, honeydew, melon, kiwifruit, 
lemon, mandarin, orange, passionfruit and paw paw 
Table 1: Table of High and Low-FODMAP foods.  
(Ashraf, A.; Elshaer, A.; Singer, R.; Wren, S.P. unpublished results, Kingston University London.) 
 
A low FODMAP diet has been shown to have a beneficial effect in randomised, single-blind, 
cross over studies. In this study spearheaded by Halmos et al, patients (n = 30 patients with 
IBS) consumed either a low FOFMAP diet or the average diet of an Australian person.(67) Their 
results showed that 70 % of subjects experienced an improvement in symptoms on the low 
FODMAP diet. This study is hindered by a low number of subjects and the subjective nature 
of the assessment of symptoms improvements. 
Although dietary intervention is well-known and relatively straightforward to implement, it is 
not without complications. The FODMAP diet is somewhat complex and with an absence of 
FODMAP information on food packaging, support from specialist dietitians is required for 
sufficient adherence, since clinical studies show that not every patient sees improvements to 
symptoms on a low FODMAP diet, patient compliance is an issue.(76) 
In addition, there is little knowledge concerning the long term health effects of being on a low 
FODMAP diet. One such issue is the alteration to the ecology of gastrointestinal bacteria due 
to the change in diet. Studies by both the Sloan and Chumpitazi groups have found a decrease 
in bacteria in the small intestine following adherence to a low FODMAP diet, which has the 
potential to negatively alter the effect the bacteria have as part of the immune system.(77,78) 
More research is needed to determine the exact changes to the bacterial ecology as a result 
of a low FODMAP diet, because the microbiology of the intestines play a key role in health 
and the immune system.  
Another concern is the increased prevalence of eating disorders caused by the need for strict 
monitoring of food intake. It has been proposed by Halmos and Gibson that patients adhering 
to strict diet controls are at an increased risk of the eating disorder orthorexia nervosa.(79) This 
disorder is linked to symptoms including an obsessive focus on food choice, planning, 
purchase, preparation and consumption; food as a source of health rather than pleasure; the 
belief that particular foods can prevent or cure disease and alter well-being.  There is a lack 
of research into such eating disorders and more study is needed into the management of such 
conditions, given the prevalence of such disorders could be between 5 and 44 % for patients 
on strict diets.(80) There are also concerns regarding potential nutritional deficiencies 
associated with being on a low FODMAP diet; more research in needed to ascertain the exact 
level of deficiency and to what extent such deficiencies cause adverse health effects.(81) 
An alternative to strict dietary controls is found in gut-directed hypnotherapy. A recent 
randomised clinical trial showed that gut-directed hypnotherapy led to similar efficacy to 
treating the symptoms of IBS as a low FODMAP diet, without the increased prevalence of 
eating disorders.(82) However, there is currently limited understanding of the brain-gut axis 
and the mechanism of how gut based hypnotherapy improves symptoms and lack of 
availability of hypnotherapists with suitable training means that such treatment may be 
inaccessible to most patients.(81) 
Xylose isomerase has been proposed as a potential treatment of FM in recent years.(83) Xylose 
isomerase is used to convert fructose to glucose in industrial settings and has been shown to 
produce no allergic response in humans.(83,84) The ability of Xylose isomerase to convert 
between glucose and fructose, shown in figure 4, has led to the proposal of its use as a 
treatment for FM.  A double-blind, placebo-controlled study showed a significant decrease in 
breath hydrogen upon oral administration of Xylose isomerase, after ingestion of fructose, as 
well as significant improvement regarding nausea and abdominal pain, two symptoms related 
to FM and IBS.(83) More research is needed to assess the long-term health effects and to 
determine which patients are best suited to treatment with xylose isomerase. 
 
         α-D-Glucopyranose      α-D-Fructofuranose 
Figure 4: The conversion of glucose to fructose by xylose isomerase.(85) 
Conclusions and future outlook 
With the increased global consumption of fructose in recent decades comes the increasing 
prevalence of IBS and other gastrointestinal complaints caused by FM. However, with limited 
understanding into the mechanism of fructose absorption and the currently inability to 
accurately diagnose FM, treatment of such disorders is somewhat difficult.  
Current treatment regimens for FM are fraught with limited understanding of the long term 
health effects of following such routines. Alternative approaches to treatment, such as the 
use of medicinal intervention, need to be investigated. It is also important that the 
relationship between SIBO and FM is investigated thoroughly, so that the symptoms of IBS 
can be accurately addressed as the result of accurate diagnosis of the causes of IBS. However, 
this is hindered significantly by the inter-relationship between these two factors and the 
similarities of the symptoms that SIBO and FM cause. Dietary intervention can prevent the 
causes of IBS, by removing the nutrients in questions from the GI tract, however, precise 
determination of the food groups responsible for symptoms can be difficult and as is the case 
with any diet, patient compliance is often the main factor in the success of these diets. 
Our understanding of FM and its role to play in various diseases is still in its infancy. However, 
it is apparent that FM may have significant role to play in a variety of diseases, not just IBS. 
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